PR for the "Book of Life"
Submitted by Sheldon Rampton on
Scientists as well as financial analysts caution that gene therapies may never come to fruition. If they do, they will be probably useful only for a handful of rare diseases. A Motley Fool financial columnist tells millions of readers, "There's no reason why the average investor should be invested in biotechnology companies.